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The rapid DNA sequencing system based on the single-stranded bacteriophage M 13 and the chain-termi- 
nator method has been used to look directly for mutational alterations. A small DNA fragment that 
primes DNA synthesis through the N-terminal 200 base pairs of the fl-galactosidase gene was prepared, 
and used to detect changes in base sequence among phages that give white plaques after treatment of the 
host cells with bleomycin. Bleomycin treatment ofE. coli in which M 13 mp2 was growing ave an increase 
in white plaque frequency. DNA sequence analysis of phage from 7 independent mutant plaques howed 
them all to have a frameshift mutation. 
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1. INTRODUCTION 
There is a high degree of correlation between 
the carcinogenicity and mutagenicity of many 
chemicals [1], and this provides the main support 
for the somatic mutation theory of carcinogenesis. 
A number of systems using bacterial [2] or mam- 
malian cells [3,4] have been developed to measure 
the mutagenicity of chemicals in order to give an 
indication of their potential role as environmental 
or experimental carcinogens. A useful addition to 
such systems would be a system which allowed the 
nature of the mutational alteration to be shown di- 
rectly by DNA sequence analysis. A prototype for 
such a system is described here, and is used to in- 
vestigate the results of exposing growing Es- 
cherichia coli cells to bleomycin. 
The single-stranded bacteriophage M13 does 
not kill its host, allowing one to induce mutations 
in it in vivo with ease simply by exposing the grow- 
ing infected host bacteria to the chemical under in- 
vestigation. M13 has been developed into a useful 
cloning vector by insertion of a portion of the lac- 
tose operon of Escherichia coli into the silent 
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region [5], the production of a recognition site for 
the restriction endonuclease EcoRI near the N-ter- 
minal coding end of the lacZ gene [6] and sub- 
sequent insertion into the EcoRI site of DNA frag- 
ments carrying other restriction endonuclease 
recognition sites [7]. The mature virion of M13 
contains a single circular single-stranded DNA 
molecule which is easily obtained pure. Thus M13 
DNA, and any other DNA that has been cloned 
into it, is in a convenient form to act as the tem- 
plate in the primed DNA synthesis reaction that 
forms the basis of the chain terminator DNA se- 
quencing method [8]. Therefore the changes in 
DNA sequence that mutations in a particular e- 
gion represent can be investigated simply and 
quickly by chain terminator DNA sequencing if a 
convenient small DNA fragment is available to act 
as a primer in the DNA synthesis reaction in the 
region of interest. The other requirements for a di- 
rect DNA sequence analysis system for the effects 
of mutagens are that a screening or selection meth- 
od for mutations is available and that the muta- 
tions do not affect the growth of the phage. In the 
prototype system described here we have used the 
N-terminal region of the /3 galactosidase gene in 
M13 mp2, which fulfills both criteria, as the target. 
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Bleomycin [9] is a glycopeptide with antibiotic 
and antineoplastic activities, which has been used 
chemically for the treatment of human cancers 
[10]. Bleomycin induces single-strand and double- 
strand breaks in vitro [10,11], and this is believed 
to be related to its antitumour activity. Bleomycin 
itself induces chromosome breaks in vivo [10,12], 
and has both recombinogenic and mutatgenic 
activity [13-15]. Here, we show directly by DNA 
sequence analysis of mutations induced by 
bleomycin that this compound is capable of 
inducing frameshift mutations in target DNA mol- 
ecules. 
2. MATERIALS AND METHODS 
2.1. DNA sequencing 
Preparation of M13 mp2 DNA was carried out 
as in [16], except hat phage were precipitated by 
the addition of polyethylene glycol [17]. Chain ter- 
minator sequencing reactions and analyses of the 
products were performed as in [8]. 
2.2. Primer preparation 
MI3 mp2 replicative form was prepared by a 
modification of the plasmid preparation method in 
[18], cells being harvested 6 h after infection with 
M13 mp2 at a multiplicity of infection of 10. Ali- 
quots (50 /~g) of M13 mp2 were digested with 
Sau3A (New England Biolabs) in 7 mM Tris-HC1 
(pH 7.4), 7 mM MgCI2, 50 mM NaC1, 1 mM di- 
thiothreitol, a 1 ttg portion end-labelled by filling 
in with DNA polymerase I (Klenow fragment) [19] 
and the primer fragment purified on an 8% thin 
polyacrylamide gel [20] using end-labelled Sau3A 
digests of pBR322 as size markers. The primer 
fragment was cut out of gel, soaked out of the in- 
tact gel in 1 ml 0.15 M NaCI, 10 mM Tris-HCl 
(pH 7.4), 0.1 mM EDTA for 24 h at 37°C, ethanol 
precipitated and used directly in primed synthesis 
reactions. 
2.3. Mutagenesis and identification of mutants 
Preparations of bleomycin that were currently in 
clinical use were kindly provided by Bristol Hellas 
(Athens). Bleomycin was dissolved in distilled 
water 2 mg/ml shortly before use. A fresh stock of 
M 13 mp2 that was isolated from a single blue pla- 
que on 1PTG-X gal plates (see below) was used in 
these experiments; its DNA sequence was deter- 
mined and found to agree with the sequence of 
this portion of the E. coli lac operon (A. Maxam et 
al., personal communication). 109 M 13 mp2 bacte- 
riophage particles (1 ~tl of a suspension at 1012/ml) 
were mixed with 108 log-phase JMI01 cells in 
0.1 ml dYT medium (16 g Difco tryptone, 10 g 
yeast extract, 5 g NaCI/I). After 10 min at room 
temperature the bacteria were diluted with 5 ml 
warm (37°C) dYT medium and incubated with 
shaking for 5 min. Unadsorbed M13 mp2 phage 
were removed by washing 5 x with ice-cold TM 
buffer (20 mM Tris-HCl (pH 7.5), 85 mM NaC1, 
0.001 M MgSO4). The pellet from the last wash 
was taken up in 1 ml cold TM and divided into 2 
× 0.5 ml aliquots. Bleomycin was added to one al- 
iquot to give final conc. 10 ptg/ml, a concentration 
which had been shown to induce an increase in 
mutation frequency in Aspergillus nidulans (N.D., 
C.S., in preparation). The other aliquot served as a 
control. After 30 min incubation at 37°C, the in- 
fective centres were spun down, washed 3 × in TM 
buffer, resuspended in 2.5 ml dTY medium, and 
0.1 ml aliquots of this distributed to sterile 1.5 ml 
conical microcentrifuge tubes containing 1 ml dYT 
at 37°C. After 1 h agitation at 37°C 2 drops of 
chloroform were added, and after 10 min the cell 
debris was removed by centrifugation. The phage 
titre in the supernatant was determined, and then 
phage were plated at 103 plaques/plate in 3 ml soft 
agar mixed with 0.3 ml an overnight culture of 
JM 101, 20 ~1 20 mg/ml 1PTG (isopropyl-thio-fl-D- 
galactoside) and 30/~1 20 mg/ml X-gal (5-bromo- 
4-chloro-3-indolyl-fl-D-galactoside, Sigma). The 
frequency of mutant phage in the supernatants 
with and without bleomycin treatment was deter- 
mined by counting the number of white (lacZ- 
mutant) plaques among the total. Only one white 
plaque from any one subculture was analysed fur- 
ther. 
3. RESULTS 
In the DNA cloning system on M 13 mp2, clones 
are identified because the insertion of foreign 
DNA at the EcoRI site leads to inactivation of the 
a-fragment of fl-galactosidase. In host strains as 
JM 101, fl-galactosidase activity is produced by the 
association of the a-fragment from M13 mp2 and 
the o~-fragment from the lac operon in the F' ca.- 
fled by the host bacteria. Thus in the presence of 
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the gratuitous inducer IPTG, fl-galactosidase ac- 
tivity is produced in the plaques where the host 
bacteria are infected by M13 mp2, and if the col- 
ourless X-gal is present his compound will be split 
and the bacteriophage plaques will be blue. Inac- 
tivation of the portion of fl-galactosidase carried 
by M13 mp2 by insertion of foreign DNA or by al- 
terations in DNA sequence induced by mutagens 
will lead to the phage making colourless plaques, 
or light blue plaques if the mutation is leaky. Thus 
MI3 mp2 has a built-in system for detecting muta- 
tions. 
The frequency of white plaques among the M 13 
mp2 population after bleomycin treatment was 35 
in 106 (in 2 x 105 plaques) whereas no white pla- 
ques occurred among 2 x 105 plaques from the 
untreated cultures. Therefore at least a 10-fold 
stimulation of the mutation rate in phage DNA 
molecules replicating within E. coli is produced by 
ATGACCATGATTACGAATTCACTGGCC 
TACTGGTACTAATGCTTAAGTGACCGG 
+ GTCGTTTTACAACGTCGTGACTGGGAAAAC 
- CAGCAAAATGTTGCAGCACTGACCCTTTTG 
+ CCTGGCGTTACCCAACTTAATCGCCTTGCA 
GGACCGCAATGGGTTGAATTAGCGGAACGT 
+ GCACA~TTCGCCAGCTGGCGTAAT 
- CGTGTA~GBGCQ~AAGCGGTGGACCGCATTA 
+ AGCGAAGAGGCCCGCACCGATC-92bp-GATC 
TCGCTTCTCCGGGCGTGGCTAG 4 
Sau3A primer 
Fig.1. DNA sequence of a portion of the E. coli lac oper- 
on insert in M 13 mp2. The sequence shown is that of the 
N-terminus of fl-galactosidase up to the 96 bp Sau3A 
primer which was used in these experiments. The tem- 
plate strand is the plus-strand, and in the sequencing re- 
action minus-strand DNA is synthesised from the left 
end of the Sau3A primer from right-to-left and bottom- 
to-top of this figure. Thus bands at the bottom of the au- 
toradiograph in fig.2 correspond to oligonucleotides 
ending a short distance to the left of the primer. The 
position of the SauA3 primer is shown by a heavy line 
ending in an arrow showing the direction of synthesis. 
The run of G-C  basepairs to which an extra basepair s
added in all 7 bleomycin-induced mutants that were 
investigated is boxed and labelled with a star. 
Fig.2. Autoradiograph of chain terminator DNA se- 
quencing analysis of M13 mp2 bl, one of the 
bleomycin-induced fl-galactosidase defective mutants. 
The position of the G run containing an extra base in 
the mutant sequence is indicated by a bracket and a star. 
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treatment with the available bleomycin prepara- 
tion at 10/~g/ml. White plaques were isolated from 
among the progeny of 7 separate bleomycin-treat- 
ed cell populations, and purified. Each mutant 
phage was grown from a well-isolated single- 
plaque and single-stranded DNA template for 
DNA sequence analyses was prepared from each 
of them as in section 2. 
Fig.l shows the location of the 96 basepair 
Sau3A DNA fragment that was used as a primer in 
the sequencing reactions. This was prepared as in 
section 2 from the double-stranded replicative 
form of MI3 mp2. Each of the 7 mutant phage 
DNA templates gave the same DNA sequence 
which differed from the M13 mp2 sequence in 
having an extra G in the minus-strand sequence 
that was synthesised in a position corresponding to 
the run of 5 Cs in the the plus-strand from 104- 
108 inclusive in fig.l, which shows the DNA se- 
quence of the portion of the fl-galactosidase g ne 
that was used. Fig.2 shows the position of the in- 
sertion mutation in an autoradiograph of a chain 
terminator sequencing experiment for one of the 
mutant DNAs, using the 96 bp Sau3A fragment as 
a primer. 
4. DISCUSSION 
The results clearly show that direct DNA se- 
quence analysis of the base sequence alterations 
induced by mutagens i  possible in this system. 
The results also show that bleomycin is capable of 
inducing frameshift mutations in a prokaryotic sys- 
tem. Bleomycin has previously been shown to act 
as a mutagen i  the fungi Saccharomyces cerevisiae 
and Aspergillus nidulans (N.D., C.S., in prepara- 
tion) [14,15]. Runs of the same base, and par- 
ticularly G-C  pairs, are usually hot-spots for 
frameshift mutations. One of the likely chemical 
modes of action of bleomycin on DNA is via inter- 
calation of the bithiazole moiety [23-25]. All 7 in- 
dependent frameshift mutations occurred at the 
same place, and comprised the insertion of an 
extra G-C  basepair (in the RF) in or at the end of 
a run of G-C  basepairs with all the Gs in the 
minus-strand and all the Cs in the plus-strand. 
This fits well with standard hypotheses [22] of the 
origin of frameshift mutations. The M13 mp2 
system is, however, not ideal for the detection and 
study of mutagenic effects of chemical compounds 
because parts of the a-region of fl-galactosidase 
can tolerate base sequence changes or even inser- 
tions and deletions that do not change the reading 
frame without loss of function sufficient o alter 
the colour phenotype of the plaque (B. Mailer- 
Hill, personal communication). Frameshift muta- 
tions result in the total loss of information from a 
large stretch of the protein, and are therefore more 
likely to be detected than single base changes that 
lead to missense mutations, or even small deletions 
and insertions that maintain the reading frame. 
Nonsense mutations hould be detectable in this 
system, and there are 9 sites in the region which we 
have studied where a single base-change would 
give rise to a nonsense mutation. Therefore, 
although we cannot conclude from these 
experiments that bleomycin only causes frameshift 
mutations, the induction of 7 frameshift but no 
nonsense mutations indicates that frameshift mu- 
tations are a major product of mutagenesis by 
bleomycin. This provides strong support for the 
hypothesis that at least part of the action of bleo- 
mycin on DNA is due to intercalation. 
These experiments have also established the fea- 
sibility of direct DNA sequence screening of the 
products of mutagenesis. A further advantage of a 
system such as this is that it relies on the produc- 
tion of any kind of 'forward' (loss of function) mu- 
tation, rather than on the more usual reversion to 
wild-type of a single-site mutation, which must be 
differentially sensitive to different ypes of muta- 
gen. We feel that this approach will be useful in 
the study of the action of mutagens, and poten- 
tially in screening environmental carcinogens for 
their mutagenic activity, and we are engaged in 
adapting the system to ensure that a wide range of 
mutational changes can be detected. 
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